investigate the effect of vitamin B 1 on menstrual bleeding and spotting after insertion of the IUD.

This study will be randomized controlled trial will be performed at the Obstetric and Gynecological Department at Beni-Suef University Hospital, Faculty of Medicine Target Population: All females with first time use of IUD inserted at the Obstetrics and Gynecology department through 3 months from the start of July 2023 till the end of November 2023.

Participants will be assigned in a 1:1 ratio to the use of vitamin B 1 or placebo, in accordance with a random table produced by an Excel program, with A being assigned to the intervention group and B to the control group. All women will sign a written informed consent prior to data collection.

Each woman within the intervention group will receive a packet containing 30 pills (vitamin B 1 or placebo), each month for three months.

Inclusion Criteria:

• Females with first time use of the IUD
• a history of normal menstrual bleeding with duration of 3 to 7 days without spotting, a menstrual cycle lasting 23 to 35 days,
• use of 10 to 14 sanitary pads per cycle before IUD insertion
• gravidity ranging between 1 and 4.

Exclusion Criteria:

• Patients with cardiac, hepatic or renal diseases.
• Patients with bleeding disorders.
• Patients with systemic diseases.